AbCellera Biologics Inc. (ABCL) Stock Performance in the Last 52 Weeks

The closing price of AbCellera Biologics Inc. (NASDAQ: ABCL) was $7.02 for the day, down -0.85% from the previous closing price of $7.08. In other words, the price has decreased by -$0.06 from its previous closing price. On the day, 2957499 shares were traded. ABCL stock price reached its highest trading level at $7.16 during the session, while it also had its lowest trading level at $6.75.

Top 5 EV Tech Stocks to Buy for 2023

According a new report published by BloombergNEF on investment in the energy transition, annual spending on passenger EVs hit $388 billion in 2022, up 53% from the year before. Like we said, the boom is accelerating – and the time to buy EV-related tech stocks is now.

Click Here to Download the FREE Report.



Our analysis of ABCL’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 10.52 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 33.84. For the most recent quarter (mrq), Quick Ratio is recorded 10.50 and its Current Ratio is at 10.50. In the meantime, Its Debt-to-Equity ratio is 0.00 whereas as Long-Term Debt/Eq ratio is at 0.00.

Upgrades & Downgrades

Insider Transactions:

Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Dec 16 when Thermopylae Holdings Ltd. bought 85,102 shares for $10.10 per share. The transaction valued at 859,249 led to the insider holds 55,859,493 shares of the business.

Thermopylae Holdings Ltd. bought 200,000 shares of ABCL for $2,292,460 on Aug 19. The 10% Owner now owns 55,844,391 shares after completing the transaction at $11.46 per share. On Jun 14, another insider, Thermopylae Holdings Ltd., who serves as the 10% Owner of the company, bought 9,173 shares for $8.05 each. As a result, the insider paid 73,842 and bolstered with 55,644,391 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABCL now has a Market Capitalization of 1.72B and an Enterprise Value of 919.01M. For the stock, the TTM Price-to-Sale (P/S) ratio is 11.22 while its Price-to-Book (P/B) ratio in mrq is 1.67. Its current Enterprise Value per Revenue stands at 5.08 whereas that against EBITDA is -69.35.

Stock Price History:

Over the past 52 weeks, ABCL has reached a high of $14.97, while it has fallen to a 52-week low of $5.53. The 50-Day Moving Average of the stock is 6.88, while the 200-Day Moving Average is calculated to be 9.80.

Shares Statistics:

ABCL traded an average of 1.91M shares per day over the past three months and 3.24M shares per day over the past ten days. A total of 287.77M shares are outstanding, with a floating share count of 203.83M. Insiders hold about 19.70% of the company’s shares, while institutions hold 46.90% stake in the company. Shares short for ABCL as of Apr 27, 2023 were 24.53M with a Short Ratio of 24.53M, compared to 23.56M on Mar 30, 2023. Therefore, it implies a Short% of Shares Outstanding of 8.55% and a Short% of Float of 15.94%.

Earnings Estimates

The firm’s stock currently is rated by 7 analysts. On average, analysts expect EPS of -$0.13 for the current quarter, with a high estimate of -$0.08 and a low estimate of -$0.18, while EPS last year was -$0.02. The consensus estimate for the next quarter is -$0.14, with high estimates of -$0.09 and low estimates of -$0.2.

Analysts are recommending an EPS of between -$0.4 and -$0.97 for the fiscal current year, implying an average EPS of -$0.59. EPS for the following year is -$0.66, with 8 analysts recommending between -$0.29 and -$1.08.

Revenue Estimates

It is expected that $90B in revenue will be generated in the current quarter, according to 7 analysts. It ranges from a high estimate of $14.7M to a low estimate of $9.95M. As of the current estimate, AbCellera Biologics Inc.’s year-ago sales were $45.92M, an estimated decrease of -72.60% from the year-ago figure. For the next quarter, 7 analysts are estimating revenue of $12.67M, a decrease of -83.10% less than the figure of -$72.60% in the same quarter last year. There is a high estimate of $15.8M for the next quarter, whereas the lowest estimate is $9M.

A total of 9 analysts have provided revenue estimates for ABCL’s current fiscal year. The highest revenue estimate was $59.7M, while the lowest revenue estimate was $40M, resulting in an average revenue estimate of $49.57M. In the same quarter a year ago, actual revenue was $485.42M, down -89.80% from the average estimate. Based on 8 analysts’ estimates, the company’s revenue will be $68.04M in the next fiscal year. The high estimate is $82M and the low estimate is $47M. The average revenue growth estimate for next year is up 37.30% from the average revenue estimate for this year.